Acknowledgments
The authors thank Suzanne Ward (BTG International) and Chip Perry (Rare Disease Therapeutics) for access to unpublished study data for this analysis.
Disclosure statement
This letter and the analyses contained were prepared without funding support. The referenced clinical trials were supported by BTG International, Inc. and Instituto Bioclon, as stated in the respective trial publications. Denver Health and Duke University have received research grant and other funding from BTG International, and Denver Health has received research funding from Instituto Bioclon. Neither author has received funds personally, nor has other interests to declare.